Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. Themis’ core lead technology, Themaxyn™ – a highly novel, patent-protected, and innovative vaccine platform which originates from a world-leading European vaccine research institute – will be used to create novel vaccines. The Company’s first vaccine targets are emerging tropical and travelers diseases, including dengue, chikungunya and yellow fever virus, and there is clear potential to expand the Themaxyn™ technology to further indications.
